Literature DB >> 19228478

Simvastatin with or without ezetimibe in familial hypercholesterolemia (the ENHANCE trial).

John A Farmer1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19228478     DOI: 10.1007/s11883-009-0013-y

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


× No keyword cloud information.
  5 in total

1.  Critical lessons from the ENHANCE trial.

Authors:  Philip Greenland; Donald Lloyd-Jones
Journal:  JAMA       Date:  2008-02-27       Impact factor: 56.272

2.  Does ENHANCE diminish confidence in lowering LDL or in ezetimibe?

Authors:  B Greg Brown; Allen J Taylor
Journal:  N Engl J Med       Date:  2008-03-30       Impact factor: 91.245

3.  Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial.

Authors:  T J Smilde; S van Wissen; H Wollersheim; M D Trip; J J Kastelein; A F Stalenhoef
Journal:  Lancet       Date:  2001-02-24       Impact factor: 79.321

4.  Carotenoid transport is decreased and expression of the lipid transporters SR-BI, NPC1L1, and ABCA1 is downregulated in Caco-2 cells treated with ezetimibe.

Authors:  Alexandrine During; Harry D Dawson; Earl H Harrison
Journal:  J Nutr       Date:  2005-10       Impact factor: 4.798

5.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.

Authors:  C Baigent; A Keech; P M Kearney; L Blackwell; G Buck; C Pollicino; A Kirby; T Sourjina; R Peto; R Collins; R Simes
Journal:  Lancet       Date:  2005-09-27       Impact factor: 79.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.